文献速递神经肿瘤功能神经外科

清醒脑映射下切除程度对II-III级胶质瘤生存的影响

Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.
PubMed 文献 · J Neurooncol · 2021-05-19

该回顾性研究分析了126例接受清醒脑手术的II/III级胶质瘤患者,评估肿瘤切除程度(EOR)与生存的关系。结果显示5年无进展生存(PFS)的EOR截断值为≥85.3%,EOR≥100%(含超全切除)组PFS显著优于EOR<90%组,尤其在IDH突变型星形细胞瘤中;而IDH野生型患者中EOR与PFS无关。

要点

  • EOR≥85.3%为5年PFS改善的截断值。
  • EOR≥100%(含超全切除)较EOR<90%显著延长PFS。
  • IDH突变型星形细胞瘤中超全/全切除与更好PFS相关。

核心结论

  • 肿瘤切除程度与II/III级胶质瘤患者生存显著相关,5年PFS的EOR截断值为≥85.3%。
  • 超全或全切除显著改善IDH突变型WHO II/III级星形细胞瘤的PFS。
  • IDH野生型弥漫性星形细胞瘤和间变性星形细胞瘤中EOR与PFS无关,需更强化治疗。

研究设计与样本

  • 回顾性分析2012年12月至2020年5月同一机构接受清醒脑手术的126例优势与非优势半球II/III级胶质瘤患者。

主要发现

  • EOR≥100%(含超全切除)组(n=47,中位生存未达到)PFS显著高于EOR<90%组(n=52,中位生存43.1个月,95%CI 37.7-48.5个月,p=0.03)。
  • 弥漫性星形细胞瘤和间变性星形细胞瘤中,EOR≥100%组(n=25,中位生存未达到)PFS显著优于EOR<100%组(n=45,中位生存35.8个月,95%CI 19.9-51.6个月,p=0.03)。
  • IDH突变型弥漫性星形细胞瘤和间变性星形细胞瘤中,超全或全切除组(n=19,中位生存未达到)PFS显著优于对照组(n=35,中位生存40.6个月,95%CI 22.3-59.0个月,p=0.02)。
  • IDH野生型弥漫性星形细胞瘤和间变性星形细胞瘤中,超全或全切除与更长PFS无关。

关键数值与推荐

  • 5年PFS的EOR截断值为≥85.3%(ROC分析)。

临床怎么用

  • 对II/III级胶质瘤,尤其是IDH突变型星形细胞瘤,应争取超全或全切除以改善PFS。
  • IDH野生型弥漫性星形细胞瘤和间变性星形细胞瘤患者,即使扩大切除也需考虑更强化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to assess the effect of the extent of resection (EOR) of tumors on survival in a series of patients with grade II and III gliomas (GII/III-gliomas) who underwent awake brain mapping. METHODS: We retrospectively analyzed 126 patients with GII/III-gliomas in the dominant and non-dominant hemisphere who underwent awake brain surgery at the same institution between December 2012 and May 2020. RESULTS: EOR cut-off values for improved progression-free survival (PFS) were determined by a receiver operator characteristic (ROC) analysis of 5-year PFS. The ROC for EOR showed a cut-off value of ≥ 85.3%. The median PFS rate of patients with GII/III-gliomas in the group with an EOR ≥ 100%, including supratotal resection (n = 47; median survival [MS], not reached), was significantly higher than that in the group with an EOR < 90% (n = 52; MS, 43.1 months; 95% CI 37.7-48.5 months; p = 0.03). In patients with diffuse astrocytomas and anaplastic astrocytomas, the group with EOR ≥ 100%, including supratotal resection (n = 25; MS, not reached), demonstrated a significantly better PFS rate than did the group with an EOR < 100% (n = 45; MS, 35.8 months; 95% CI 19.9-51.6 months; p = 0.03). Supratotal or gross total resection was correlated with better PFS in IDH-mutant type of diffuse astrocytomas and anaplastic astrocytomas (n = 19; MS, not reached vs. n = 35; MS, 40.6 months; 95% CI 22.3-59.0 months; p = 0.02). By contrast, supratotal or gross total resection was not associated with longer PFS rates in patients with IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas. CONCLUSIONS: The present study demonstrates a significant association between tumor EOR and survival in patients with GII/III gliomas. The EOR cut-off value for 5-year PFS was ≥ 85.3%. It is noteworthy that supratotal or gross total resection significantly correlated with better PFS in IDH-mutant type of WHO grade II and III astrocytic tumors. In light of our finding that EOR did not correlate with PFS in patients with aggressive IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas, we suggest treatments that are more intensive will be needed for the control of these tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Motomura K, Chalise L, Ohka F, et al. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. J Neurooncol. 2021. PMID: 34009509. doi:10.1007/s11060-021-03776-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。